Cargando…
Halobetasol propionate lotion 0.05% in patients 12 to 16 years 11 months of age with plaque psoriasis: Results of an open-label study evaluating adrenal suppression potential
BACKGROUND: The effects of halobetasol propionate (HBP) lotion 0.05% on the hypothalamic-pituitary-adrenal (HPA) axis have not been previously evaluated in adolescents. OBJECTIVE: To examine the effect of HBP on HPA axis suppression in patients aged <17 years with plaque psoriasis. METHODS: In th...
Autores principales: | Laquer, Vivian, Nguyen, Andrea, Squittieri, Nicholas, Nguyen, Tien |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8626834/ https://www.ncbi.nlm.nih.gov/pubmed/34870246 http://dx.doi.org/10.1016/j.jdin.2021.10.003 |
Ejemplares similares
-
Impact of Halobetasol Propionate and Tazarotene Lotion 0.01%/0.045% in the Management of Plaque Psoriasis in Adults
por: Reddy, Vidhatha, et al.
Publicado: (2020) -
Real-world treatment outcomes with halobetasol propionate 0.01%/tazarotene 0.045% lotion in patients with mild-to-moderate plaque psoriasis: A Canadian multicenter retrospective chart review
por: Vender, Ronald, et al.
Publicado: (2022) -
Fixed-Combination Halobetasol Propionate and Tazarotene in the Treatment of Psoriasis: Narrative Review of Mechanisms of Action and Therapeutic Benefits
por: Lebwohl, Mark G., et al.
Publicado: (2021) -
Matching-Adjusted Indirect Comparison of Long-Term Efficacy and Safety Outcomes for Calcipotriol Plus Betamethasone Dipropionate Foam Versus Halobetasol Proprionate Plus Tazarotene Lotion in the Treatment of Plaque Psoriasis
por: Adam, David N., et al.
Publicado: (2022) -
Topical Treatment of Truncal Acne with Tretinoin Lotion 0.05% and Azelaic Acid Foam
por: St. Surin-Lord, Sharleen, et al.
Publicado: (2020)